gauthier_therapy

05 vs placeboreminyl and not statistically different

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: 1 2 3 4 5 6 7 0 3 6 Months 9 12 Deterioration Placebo/Reminyl® 24 mg *P <0 .05 vs Placebo/Reminyl® and not statistically different from baseline. Reminyl® 24 mg/Reminyl® 24 mg Historical placebo group © TND 2005 LS mean change from baseline ± SE Cognition: Severe Impairment Battery (SIB) p<0.0001 6 p=0.0051 p<0.0009 p=0.0078 4 p<0.0001 p=0.0001 Clinical improvement 2 0 Baseline -2 Donepezil -4 -6 Clinical decline Placebo 0 4 8 12 18 24 ITT LOCF Study week Donepeziln=139 130 115 123 119 120 (139) Placebo n=145 139 119 128 128 126 (145) © TND 2005 FUNCTIONAL OUTCOMES Disability Assessment in Dementia (DAD) © TND 2005 LS mean change from baseline ± SE Functional autonomy: Disability assessment for dementia (DAD) 4 Clinical improvement p=0.0037 2 p<0.0001 p<0.0001 0 Baseline -2 -4 Clinical decline -6 -8 Donepezil -10 Placebo -12 0 12 Study week 24 ITT LOCF Donepeziln=134 125 121 (134) Placebo n=140 129 126 (140) © TND 2005 BEHAVIOR OUTCOMES NeuroPsychiatric Inventory (NPI) Behave AD © TND 2005 Reminyl delays the emergence of behavioral symptoms Reminyl (Tariot: GAL-USA-10) (Tariot: Dose Increment –3 Improvement Dose Increment –2 –1 Mean (± SE) Change From Baseline In NPI * 0 1 2 3...
View Full Document

This document was uploaded on 03/07/2014 for the course BIOLOGY BIO at NYU.

Ask a homework question - tutors are online